PDF(Pubmed)
Abstract：
Malignant bone tumors, including primary bone cancer and metastatic bone tumors, are a significant clinical challenge due to their high frequency of presentation, poor prognosis and lack of effective treatments and therapies. Bone tumors are often accompanied by skeletal complications such as bone destruction and cancer-induced bone pain. However, the mechanisms involved in bone cancer progression, bone metastasis and skeletal complications remain unclear. Lysophosphatidic acid (LPA), an intercellular lipid signaling molecule that exerts a wide range of biological effects mainly through specifically binding to LPA receptors (LPARs), has been found to be present at high levels in the ascites of bone tumor patients. Numerous studies have suggested that LPA plays a role in primary malignant bone tumors, bone metastasis, and skeletal complications. In this review, we summarize the role of LPA signaling in primary bone cancer, bone metastasis and skeletal complications. Modulating LPA signaling may represent a novel avenue for future therapeutic treatments for bone cancer, potentially improving patient prognosis and quality of life.
摘要：
恶性骨肿瘤，包括原发性骨癌和转移性骨肿瘤，是一个重大的临床挑战，因为它们的出现频率很高，预后差，缺乏有效的治疗方法。骨肿瘤通常伴有骨骼并发症，例如骨破坏和癌症引起的骨痛。然而,参与骨癌进展的机制，骨转移和骨骼并发症仍不清楚。溶血磷脂酸(LPA),一种细胞间脂质信号分子，主要通过与LPA受体（LPAR）特异性结合发挥广泛的生物学效应，已发现在骨肿瘤患者的腹水中以高水平存在。大量研究表明，LPA在原发性恶性骨肿瘤中起作用。骨转移,和骨骼并发症。在这次审查中,我们总结了LPA信号在原发性骨癌中的作用，骨转移和骨骼并发症。调节LPA信号可能代表未来骨癌治疗的新途径。可能改善患者预后和生活质量。
